These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 27387831)

  • 1. Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
    Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D
    Orphanet J Rare Dis; 2016 Jul; 11(1):92. PubMed ID: 27387831
    [No Abstract]   [Full Text] [Related]  

  • 2. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
    Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():199. PubMed ID: 25519680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
    Attarian S; Young P; Brannagan TH; Adams D; Van Damme P; Thomas FP; Casanovas C; Kafaie J; Tard C; Walter MC; Péréon Y; Walk D; Stino A; de Visser M; Verhamme C; Amato A; Carter G; Magy L; Statland JM; Felice K
    Orphanet J Rare Dis; 2021 Oct; 16(1):433. PubMed ID: 34656144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
    Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
    Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.
    Micallef J; Attarian S; Dubourg O; Gonnaud PM; Hogrel JY; Stojkovic T; Bernard R; Jouve E; Pitel S; Vacherot F; Remec JF; Jomir L; Azabou E; Al-Moussawi M; Lefebvre MN; Attolini L; Yaici S; Tanesse D; Fontes M; Pouget J; Blin O
    Lancet Neurol; 2009 Dec; 8(12):1103-10. PubMed ID: 19818690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary motor and sensory neuropathies or Charcot-Marie-Tooth diseases: an update.
    Tazir M; Hamadouche T; Nouioua S; Mathis S; Vallat JM
    J Neurol Sci; 2014 Dec; 347(1-2):14-22. PubMed ID: 25454638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
    Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM
    Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.
    Fledrich R; Schlotter-Weigel B; Schnizer TJ; Wichert SP; Stassart RM; Meyer zu Hörste G; Klink A; Weiss BG; Haag U; Walter MC; Rautenstrauss B; Paulus W; Rossner MJ; Sereda MW
    Brain; 2012 Jan; 135(Pt 1):72-87. PubMed ID: 22189569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.
    Mandel J; Bertrand V; Lehert P; Attarian S; Magy L; Micallef J; Chumakov I; Scart-Grès C; Guedj M; Cohen D
    Orphanet J Rare Dis; 2015 Jun; 10():74. PubMed ID: 26070802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An anterior ankle-foot orthosis improves walking economy in Charcot-Marie-Tooth type 1A patients.
    Menotti F; Laudani L; Damiani A; Mignogna T; Macaluso A
    Prosthet Orthot Int; 2014 Oct; 38(5):387-92. PubMed ID: 24100074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurophysiology and molecular genetics of Charcot-Marie-Tooth type 1 neuropathy in Croatian children: follow-up study.
    Barisić N; Mihatov I
    Croat Med J; 2000 Sep; 41(3):306-13. PubMed ID: 10962051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sonography of the median nerve in Charcot-Marie-Tooth disease.
    Martinoli C; Schenone A; Bianchi S; Mandich P; Caponetto C; Abbruzzese M; Derchi LE
    AJR Am J Roentgenol; 2002 Jun; 178(6):1553-6. PubMed ID: 12034637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with foot and ankle strength in healthy preschool-age children and age-matched cases of Charcot-Marie-Tooth disease type 1A.
    Rose KJ; Burns J; North KN
    J Child Neurol; 2010 Apr; 25(4):463-8. PubMed ID: 19671887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of messenger RNA for peripheral myelin protein 22 in biopsied peripheral nerves of patients with Charcot-Marie-Tooth disease type 1A.
    Yoshikawa H; Nishimura T; Nakatsuji Y; Fujimura H; Himoro M; Hayasaka K; Sakoda S; Yanagihara T
    Ann Neurol; 1994 Apr; 35(4):445-50. PubMed ID: 7512319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Charcot-Marie-Tooth Neuropathy Score in children with type 1A disease.
    Haberlová J; Seeman P
    Pediatr Neurol; 2010 Dec; 43(6):407-10. PubMed ID: 21093731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofibromatosis type 1 associated with Charcot-Marie-Tooth type 1A.
    Koc F; Guzel AI
    J Dermatol; 2009 May; 36(5):306-11. PubMed ID: 19383003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study.
    Verhamme C; van Schaik IN; Koelman JH; de Haan RJ; de Visser M
    Brain; 2009 Dec; 132(Pt 12):3252-62. PubMed ID: 19843647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice.
    Klein D; Patzkó Á; Schreiber D; van Hauwermeiren A; Baier M; Groh J; West BL; Martini R
    Brain; 2015 Nov; 138(Pt 11):3193-205. PubMed ID: 26297559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients homozygous for the 17p11.2 duplication in Charcot-Marie-Tooth type 1A disease.
    LeGuern E; Gouider R; Mabin D; Tardieu S; Birouk N; Parent P; Bouche P; Brice A
    Ann Neurol; 1997 Jan; 41(1):104-8. PubMed ID: 9005872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.